NASDAQ:QNRX Quoin Pharmaceuticals Q1 2025 Earnings Report $5.48 -0.52 (-8.67%) Closing price 04/17/2025 03:58 PM EasternExtended Trading$5.49 +0.01 (+0.18%) As of 04/17/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History Quoin Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.11Beat/MissN/AOne Year Ago EPSN/AQuoin Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQuoin Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Quoin Pharmaceuticals Earnings HeadlinesQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Sees Significant Drop in Short InterestApril 16 at 2:52 AM | americanbankingnews.comQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.com100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust, the 2008 crisis, and the crash of 2020. Now, it’s flashing again. Eliza Lasky of Weiss Advocate reveals what this forgotten signal says about the next big move — and how smart investors are preparing.April 18, 2025 | Weiss Ratings (Ad)Quoin Pharmaceuticals Ltd – ADR trading halted, news pendingApril 9, 2025 | markets.businessinsider.comImmunic (NASDAQ:IMUX) versus Quoin Pharmaceuticals (NASDAQ:QNRX) Head-To-Head SurveyApril 8, 2025 | americanbankingnews.comQuoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirementsApril 6, 2025 | uk.investing.comSee More Quoin Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email. Email Address About Quoin PharmaceuticalsQuoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.View Quoin Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
